CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 10 No. 3
The Emmanoulides/Miles/Mitsuyasu Article Reviewed 

Pathogenesis of AIDS-Related Kaposi's Sarcoma

By

Parkash G. Gil, MD, University of Southern California, Los Angeles | March 1, 1996


Emmanoulides, Miles, and Mitsuyasu have written an excellent review summarizing our current understanding of the pathogenesis of AIDS-related Kaposi's sarcoma (AIDS/KS). The authors cover what is currently well established and also provide their viewpoint on future developments in AIDS/KS. My commentary will highlight some of the major questions related to this complex disease.

It is well known that AIDS/KS develops most frequently in homosexual or bisexual men. This feature is difficult to reconcile with the present understanding of the disease. For example, it is unlikely that human herpesvirus type 8 (HHV-8), also called KS-related herpesvirus (KSHV), spreads only in this population, as numerous studies indicate that HHV-8 is widespread. Human herpesvirus type 8 has been detected in HIV-negative patients with classic KS, individuals with the African form of KS, and those who develop KS after a renal transplant. This virus also is present in patients with other malignant and premalignant skin disorders who do not have KS or HIV infection [1]. The cause of the differences in the risk for KS in patients with HHV-8 is thus unclear.

Role of Sex Hormones

Kaposi's sarcoma develops predominantly in men with or without HIV infection and is exceedingly rare in women. It is natural to propose that sex hormones may be responsible for these differences in the development of KS. It is well established that sex hormones are ligands, which, upon binding to their cognate receptors, activate their respective receptors and regulate various genes directly by binding to response elements or by protein/protein interaction [2]. The lack of androgen and estrogen receptors in KS tissue, however, argues against a direct effect of these hormones in the tumor [3]. It is possible that hormone metabolites that do not require specific receptors may have direct effects. Alternatively, these hormones may act indirectly by regulating paracrine growth factors at distant sites.

I believe that sex hormones have an important role in AIDS/KS based on the epidemiology of the disease and the findings from HIV tat transgenic mice that develop KS-like vascular tumors in the skin of male mice only. The role of sex hormones could potentially be studied by treating male HIV tat transgenic mice with female or male sex hormones and then measuring the decrease or increase in the rate of tumor development. Similarly, female mice could be treated with androgens, with the expectation that KS-like tumors would develop only in hormone-treated animals. These experiments could also be done by cross-breeding HIV tat transgenic animals with transgenics overexpressing androgen or estrogen receptors. Understanding how sex hormones influence KS is likely to have a broader application in vascular biology.

A Variable Course

AIDS/KS has an extremely variable course, which can be dormant in some individuals and rapidly progressive in others. The course of AIDS/KS is often independent of the host's immune competence. An understanding of this phenomenon is likely to provide insight into the biology of this tumor. For example, indolent disease may represent a premalignant state or lower grade of malignancy that can evolve to a high-grade malignancy--a situation analogous to chronic lymphocytic leukemia undergoing Richter's transformation.

Definition of genetic events in AIDS/KS and the order of such events, similar to that defined for colon cancer, not only would provide a better understanding of the disease but also could result in diagnostic tools to predict outcome. For example, KS has long been considered to be a benign proliferative process, at least in some cases. It is possible that the recently described herpesvirus (HHV-8) or another putative agent can directly or indirectly induce a benign or premalignant lesion prior to the activation of oncogene(s) or loss of tumor-suppressor gene(s). These benign lesions may respond to antiviral therapy. However, a neoplastic tumor with genetic alterations would be highly unlikely to respond to antiviral therapy.

The isolation and long-term propagation of KS spindle cells and, more recently, the isolation of transformed tumor cells lines [4,5] have provided a better understanding of autocrine and paracrine growth factors, as outlined by Emmanoulides and colleagues. The hierarchial role of these factors remains to be established. It is likely that multiple factors are induced in response to one or more genetic events.

In addition, the isolation of transformed cell lines documents that KS is a clonal disease, at least in some cases. Rabkin et al have also documented clonality in KS by testing primary tumor tissues from women with KS by studying heterozygosity of the androgen receptor loci using the x-linked methylation assay [6]. Studies of a large number of women with KS and examination of early and late disease would help determine whether KS is clonal from the onset or whether it begins as a polyclonal disease with evolution to a clonal disease over time.

A Remarkable Discovery

My final comment relates to the role of HHV-8 in the development of KS. Chang and Moore have made a remarkable discovery using the representational difference assay (RDA) pioneered by Widler's group. Chang and Moore have shown the presence of unique DNA sequences in the KS tumor tissue that are not present in normal skin from the same patient. The DNA sequences represent a new herpesvirus, currently known as human herpesvirus (HHV).

It is tempting to speculate that HHV-8 is the etiologic agent for KS. However, at present, no conclusive data exist to support or refute its role. Additional work is required to address this issue. Such research will need to isolate and propagate the virus, determine the permissive cell types (in addition to B lymphocytes), determine its tranforming ability, possibly by taking leads from the work performed on similar herpesviruses, including Epstein-Barr virus and herpesvirus saimiri.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.



Christos Emmanoulides, MD, Steven A. Miles, MD and Ronald T. Mitsuyasu, MD


1. Rady PL, Yen A, Rollefson JL, et al: Herpes virus like DNA sequences in non-Kaposi's sarcoma skin lesions of transplant patients. Lancet 345:1339-1340, 1995.

2. Chambon P: The retinoid signaling pathway: Molecular and genetic analyses. Semin Cell Biol 5, 115-125, 1994.

3. Zeigler JL, Katongole-Mbidde E, Wsbinga H, et al: Absence of sex-hormone receptors in Kaposi's Sarcoma. Lancet 345: 925, 1995.

4. Lunardi-Iskandar Y, Gill PS, Lam VH, et al: Isolation and characterization of an immortal neoplastic cell line (KS Y-1) from AIDS-associated Kaposi's Sarcoma. J Natl Cancer Inst 87:974-981, 1995.

5. Lunardi-Iskandar y, Bryant JL, Zeman RA, et al: Tumorigenisis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 375:64-68, 1995.

6. Rabkin C, Bedi G, Musaba E, et al: AIDS-related Kaposis's sarcoma is a clonal neoplasm. Clin Cancer Res 1:257-260, 1995.


 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • Skin Lesions
  • “This Is My Last Day on Earth”
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
  • Staying Fit Could Ward Off Lung and Colorectal Cancer for Middle-Age Men
  • Obesity Impairs Efficacy of L-Asparaginase in Leukemia Treatment
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Preventing Exposure to Hazardous Drugs
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy